Sanofi India Ltd

Filing Status

• Show Cause Notice received from State Tax Officer Ahmedabad relating to GST for FY 2022-23.

Key Details

• Discrepancies alleged between E-Way Bill values and GSTR-1 disclosures.
• GSTR-9C vs GSTR-1 turnover reconciliation issues.
• Short reversal of input tax credit; ineligible input tax credits alleged.

Financial Implications

• Tax, interest and penalty demand of Rs 16,40,07,641; company not envisaging adverse financial impact.

Response Status

• Company is preparing reply within prescribed time after consulting tax advisors.

Key transaction details

• Acquirer: Sanofi Healthcare India Private Limited; Transferor: Hoechst GmbH (promoter).
• Inter-se transfer among promoter group via block deal on the stock exchange.
• Shares acquired: 3,500,000 representing 15.20% of the target's equity share capital.
• Aggregate promoter and promoter group holding remains unchanged post-transaction.
• Exemption from open offer under Regulation 10(1)(a)(iii) of SAST Regulations.
• Price paid: Rs 3,052 per share.
• Disclosure under Regulation 10(5) filed within the regulatory timeline.
• Post-transaction shareholding: acquirer 15.20%, transferor 45.18%.

Promoter transfer details

• Inter-se transfer among promoter group through a block deal on the Stock Exchange.
• Sanofi Healthcare India Private Limited acquired 3,500,000 equity shares; post-transaction holding 15.20%.
• Transaction value disclosed: INR 10,68,20,00,000.
• Acquisition date: 24/09/2026; intimation to company: 25/09/2026.
• Mode: inter-se transfer within promoter group; exchange: NSE.

Promoter share transfer

• Promoter-to-promoter transfer: Hoechst GmbH transfers shares to Sanofi Healthcare India via block deal on stock exchange.

Governance / Compliance

• Show Cause Notice dated 25 Sep 2026 under Karnataka GST Act alleging excess input tax credit.
• Tax demand Rs 14,43,01,828 plus interest Rs 9,30,74,679; total Rs 23,73,76,507.
• Company responding and expects no adverse impact; reply to be submitted within prescribed period.

Key details

• Target Company: Sanofi India Limited.
• Disclosing Party: Hoechst GmbH (Seller) with promoter-group PACs.
• Promoter-group status: seller and PACs are promoter group.
• Transaction type: disposal of 3,500,000 equity shares.
• Pre-transaction: Hoechst 13,904,722 shares (60.38%); PACs 4,865 shares (0.02%).
• Shares sold: 3,500,000, 15.20% of total.
• Mode: inter-se transfer among promoter group via block deal on the stock exchange.
• Instrument: equity shares.
• Post-transaction: Hoechst 10,404,722 shares (45.18%); PACs 3,504,865 shares (15.22%).
• Date of transaction: 24 September 2026.
• Equity share capital before/after: Rs 230,306,220; diluted capital: Rs 230,306,220.

Transaction overview

• Target Company: Sanofi India Limited.
• Acquirer: Sanofi Healthcare India Private Limited; PAC includes Hoechst GmbH and other promoter-group entities.
• Transaction type: Acquisition via inter-se transfer within promoter-group block deal.
• Date of transaction: 24 September 2026.
• Mode: Block deal on Stock Exchange.

Pre-Transaction Holding

• Acquirer pre-holding: voting rights Nil; promoter-group excluding acquirer: 13,909,587 shares, 60.40%.
• Total pre-holding shares: 13,909,587 (60.40%).

Transaction Details

• Shares carrying voting rights acquired: 3,500,000; 15.20% of total.
• Mode of acquisition: Inter-se transfer; block deal on Stock Exchange.

Post-Transaction Holding

• Post-transaction: Acquirer holds 3,500,000 shares (15.20%).
• Hoechst GmbH holdings after: 10,404,722 shares (45.18%).
• Total promoter-group holding after: 13,909,587 shares (60.40%).

Capital context

• Equity share capital before: Rs. 230,306,220 (23,030,622 shares).
• Equity share capital after: Rs. 230,306,220 (23,030,622 shares).
• Total diluted share/voting capital after: Rs. 230,306,220 (23,030,622 shares).

Target and promoter details

• Target company: Sanofi India Limited.
• Acquirer: Sanofi Healthcare India Private Limited; PACs include Hoechst GmbH and promoter-group entities.
• Acquirer belongs to the promoter group of the Target.
• Stock exchanges: BSE and NSE.

Acquisition specifics

• Date of acquisition: 24 September 2026.
• Mode: Inter-se transfer within promoter group via block deal on stock exchanges.
• Pre-acquisition: Acquirer held Nil; PAC held 13,909,587 shares (60.40%).
• Shares acquired: 3,500,000 voting shares (15.20%).
• Post-acquisition: Acquirer 3,500,000 (15.20%); PAC 10,409,587 (45.20%). Total 13,909,587 (60.40%).

Capital and encumbrances

• Equity share capital before/after: 23,030,622 shares; Rs 230,306,220.
• Total diluted share/voting capital after: 23,030,622 shares; Rs 230,306,220.
• Encumbrances/warrants: Nil.

Target & Disclosing Parties

• Target Company: Sanofi India Limited.
• Seller: Hoechst GmbH; promoter group.
• PACs include Sanofi Healthcare India Private Limited and other promoters.

Transaction Details

• Transaction type: sale/acquisition via inter-se transfer within promoter group.
• Date of transaction: 24 September 2026.
• Mode: inter-se transfer; block-deal mechanism on stock exchange.
• Pre-transaction holding: Hoechst 13,904,722 shares (60.38%); PACs 4,865 (0.02%).
• Total pre-transaction voting capital: 13,909,587 shares (60.40%).
• Shares acquired/sold: 3,500,000 shares (15.20%).
• Post-transaction: Hoechst 10,404,722 shares (45.18%); PACs 3,504,865 shares (15.22%).
• Equity share capital before/after: Rs 230,306,220 (23,030,622 shares).
• Total diluted capital: Rs 230,306,220 (23,030,622 shares).

Sanofi India Limited — Trading window closed from 1st October 2026 till 48 hours after the announcement of the Results to the stock exchanges for the Unaudited Financial Results of the Company for the quarter and nine months ending 30th September 2026